ENG and systemic sclerosis: As already suggested, additional studies highlighting ENG involvement in SSc, both clinical (i.e., further evaluations of sENG concentrations in patients with SSc in different stages of disease, with different pathotypes and compared to other connective tissue diseases) or molecular (i.e., Short vs. Long ENG, involvement of post-transcriptional mechanisms in ENG expression regulation), can pave the way to novel diagnostic, prognostic and therapeutic approaches ameliorating patients' global health and quality of life.